Efficacy and Safety Comparison of Etoposide Combined with PEG-rhG-CSF

Overview

This study evaluates the efficacy and safety of high-dose etoposide combined with PEG-rhG-CSF versus rhG-CSF for mobilizing hematopoietic stem cells in patients with multiple myeloma and lymphoma. Results indicate that PEG-rhG-CSF significantly improves CD34+ cell yield and reduces febrile infections.

Background

Efficient mobilization of hematopoietic stem cells is crucial for successful autologous stem cell transplantation (ASCT) in multiple myeloma and lymphoma patients. Current mobilization strategies often involve granulocyte colony-stimulating factors (G-CSF), but the efficacy of newer agents like PEG-rhG-CSF remains underexplored. Understanding the comparative effectiveness of these agents can enhance patient outcomes in stem cell transplantation.

Data Highlights

Key Findings

• Mobilization success exceeded 90% in both treatment groups.
• PEG-rhG-CSF resulted in a significantly higher total CD34+ cell yield compared to rhG-CSF.
• A greater proportion of patients in the PEG-rhG-CSF group were classified as optimal mobilizers.
• The first-day collection success rate was higher in the PEG-rhG-CSF group.
• Fewer apheresis sessions and shorter mobilization duration were noted with PEG-rhG-CSF.
• Lower incidence of febrile infections was observed in patients receiving PEG-rhG-CSF.

Clinical Implications

The findings suggest that PEG-rhG-CSF may be a more effective and safer option for stem cell mobilization in patients undergoing ASCT for multiple myeloma and lymphoma. Clinicians should consider this regimen to enhance mobilization outcomes and reduce infection risks.

Conclusion

High-dose etoposide combined with PEG-rhG-CSF shows superior efficacy and safety compared to the traditional combination with rhG-CSF, indicating a potential shift in standard practice for stem cell mobilization.

Related Resources & Content

1. Bone Marrow Transplantation, 2024 -- Evaluating the Efficacy of Stem Cell Mobilization with Chemotherapy and G-CSF Compared to G-CSF Alone in Patients with Myeloma: A Randomized Phase II Open-Label Non-Inferiority Study
2. Blood Cancer Journal, 2024 -- Phase II Trial Assessing a New CXCR2 Agonist and Plerixafor for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients
3. npj Digital Medicine, 2026 -- Forecasting Complications for Risk Assessment of Chemotherapy-Induced Stem Cell Mobilization in Multiple Myeloma
4. Bone Marrow Transplantation — Comparison of Cyclophosphamide and Salvage Chemotherapy with G-CSF for Chemo-Mobilization in Asian Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
5. The EBMT Handbook
6. Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma - ScienceDirect
7. Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial - ScienceDirect